Entasis Therapeutics Holdings Inc. (ETTX) Prices 5M Share IPO at $15/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq climb as soft inflation dampens Fed rate hike expectations
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 flat as higher bond yields counter tech optimism
Entasis Therapeutics Announces Pricing of Initial Public Offering
September 25, 2018 9:56 PM EDTWALTHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has priced its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. The gross proceeds to Entasis, before deducting underwriting discounts, commissions and offering expenses, are expected to be approximately $75 million.  All of the common stock is being offered by Entasis. In addition, Entasis has granted the underwriters a 30-day option to purchase up... More
